XML 44 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
STOCK-BASED COMPENSATION (Tables)
9 Months Ended
Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Schedule of non-cash compensation expense related to equity awards
Non-cash compensation related to equity awards is included in the following line items in the accompanying consolidated statements of operations and comprehensive income (in thousands):
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2018
 
2017
 
2018
 
2017
Cost of revenue
$
123


$
41

 
$
260

 
$
129

Selling and marketing expense
1,577


1,366

 
4,511

 
2,543

General and administrative expense
8,388


5,864

 
25,617

 
8,684

Product development
2,009


667

 
3,996

 
1,712

Total non-cash compensation
$
12,097

 
$
7,938

 
$
34,384

 
$
13,068

Summary of changes in outstanding stock options
A summary of changes in outstanding stock options is as follows:
 
Number of Options
 
Weighted
Average
Exercise
Price
 
Weighted
Average
Remaining
Contractual
Term
 
Aggregate
Intrinsic
Value(a)
 
 
 
(per option)
 
(in years)
 
(in thousands)
Options outstanding at January 1, 2018
1,863,739

 
$
30.70

 
 
 
 

Granted (b)
58,901

 
317.31

 
 
 
 

Exercised
(971,211
)
 
16.31

 
 
 
 

Forfeited
(6,425
)
 
299.89

 
 
 
 

Expired

 

 
 
 
 

Options outstanding at September 30, 2018
945,004

 
61.53

 
5.42
 
$
163,927

Options exercisable at September 30, 2018
772,651

 
$
25.03

 
4.64
 
$
158,473

(a)
The aggregate intrinsic value represents the total pre-tax intrinsic value (the difference between the Company's closing stock price of $230.10 on the last trading day of the quarter ended September 30, 2018 and the exercise price, multiplied by the number of shares covered by in-the-money options) that would have been received by the option holder had the option holder exercised these options on September 30, 2018. The intrinsic value changes based on the market value of the Company's common stock.
(b)
During the nine months ended September 30, 2018, the Company granted stock options to certain employees and members of the board of directors with a weighted average grant date fair value per share of $161.58, calculated using the Black-Scholes option pricing model, which vesting periods include (a) immediate vesting on grant date (b) one year from grant date (c) two years from the grant date, (d) three years from the grant date and (e) four years from the grant date.
A summary of the changes in outstanding stock options with performance conditions is as follows:
 
Number of Options
 
Weighted
Average
Exercise
Price
 
Weighted
Average
Remaining
Contractual
Term
 
Aggregate
Intrinsic
Value(a)
 
 
 
(per option)
 
(in years)
 
(in thousands)
Options outstanding at January 1, 2018
37,877

 
$
308.90

 
 
 
 

Granted

 

 
 
 
 

Exercised

 

 
 
 
 

Forfeited

 

 
 
 
 

Expired

 

 
 
 
 

Options outstanding at September 30, 2018
37,877

 
$
308.90

 
9.20
 
$

Options exercisable at September 30, 2018

 
$

 
0
 
$

(a)
The aggregate intrinsic value represents the total pre-tax intrinsic value (the difference between the Company's closing stock price of $230.10 on the last trading day of the quarter ended September 30, 2018 and the exercise price, multiplied by the number of shares covered by in-the-money options) that would have been received by the option holder had the option holder exercised these options on September 30, 2018. The intrinsic value changes based on the market value of the Company's common stock.
Schedule of stock option valuation assumptions
For purposes of determining stock-based compensation expense, the weighted average grant date fair value per share of the stock options was estimated using the Black-Scholes option pricing model, which requires the use of various key assumptions. The weighted average assumptions used are as follows:
Expected term (1)
5.00 - 6.34 years

Expected dividend (2)

Expected volatility (3)
50% - 53%

Risk-free interest rate (4)
2.33% - 2.90%

(1)
The expected term of stock options granted was calculated using the "Simplified Method," which utilizes the midpoint between the weighted average time of vesting and the end of the contractual term. This method was utilized for the stock options due to a lack of historical exercise behavior by the Company's employees.
(2)
For all stock options granted in 2018, no dividends are expected to be paid over the contractual term of the stock options, resulting in a zero expected dividend rate.
(3)
The expected volatility rate is based on the historical volatility of the Company's common stock.
(4)
The risk-free interest rate is specific to the date of grant. The risk-free interest rate is based on U.S. Treasury yields for notes with comparable expected terms as the awards, in effect at the grant date.
For purposes of determining stock-based compensation expense, the weighted average grant date fair value per share of the stock options was estimated using the Monte Carlo simulation model, which requires the use of various key assumptions. The weighted average assumptions used are as follows:
Expected term (1)
7.00 - 7.15 years

Expected dividend (2)

Expected volatility (3)
50%

Risk-free interest rate (4)
2.38% - 2.81%

(1)
The expected term of stock options with a market condition granted was calculated using the midpoint between the weighted average time of vesting and the end of the contractual term.
(2)
For all stock options with a market condition granted in 2018, no dividends are expected to be paid over the contractual term of the stock options, resulting in a zero expected dividend rate.
(3)
The expected volatility rate is based on the historical volatility of the Company's common stock.
(4)
The risk-free interest rate is specific to the date of grant. The risk-free interest rate is based on U.S. Treasury yields for notes with comparable expected terms as the awards, in effect at the grant date.
Schedule of changes in outstanding non-vested RSUs and restricted stock
A summary of the changes in outstanding nonvested restricted stock units ("RSUs"), exclusive of RSUs granted to the Chairman and Chief Executive Officer in 2018 described below, is as follows:
 
RSUs
 
Number of Units
 
Weighted Average Grant Date Fair Value
 
 
 
(per unit)
Nonvested at January 1, 2018
152,829

 
$
121.68

Granted
90,343

 
295.49

Vested
(63,980
)
 
99.58

Forfeited
(9,288
)
 
218.95

Nonvested at September 30, 2018
169,904

 
$
217.10

 
Schedule of changes in outstanding nonvested RSUs with performance conditions
A summary of the changes in outstanding nonvested RSUs with performance conditions is as follows:
 
RSUs with Performance Conditions
 
Number of Units
 
Weighted Average Grant Date Fair Value
 
 
 
(per unit)
Nonvested at January 1, 2018
111,205

 
$
160.34

Granted

 

Vested
(12,226
)
 
106.18

Forfeited
(2,652
)
 
113.22

Nonvested at September 30, 2018
96,327

 
$
168.52

Schedule of changes in outstanding stock options with market conditions
A summary of changes in outstanding stock options with market conditions is as follows:
 
Number of Options with Market Conditions
 
Weighted
Average
Exercise
Price
 
Weighted
Average
Remaining
Contractual
Term
 
Aggregate
Intrinsic
Value(a)
 
 
 
(per option)
 
(in years)
 
(in thousands)
Options outstanding at January 1, 2018
402,694

 
$
183.80

 
 
 
 

Granted (b)
44,499

 
351.70

 
 
 
 

Exercised

 

 
 
 
 

Forfeited

 

 
 
 
 

Expired

 

 
 
 
 

Options outstanding at September 30, 2018
447,193

 
200.51

 
8.87
 
$
18,645

Options exercisable at September 30, 2018

 
$

 
0
 
$

(a)
The aggregate intrinsic value represents the total pre-tax intrinsic value (the difference between the Company's closing stock price of $230.10 on the last trading day of the quarter ended September 30, 2018 and the exercise price, multiplied by the number of shares covered by in-the-money options) that would have been received by the option holder had the option holder exercised these options on September 30, 2018. The intrinsic value changes based on the market value of the Company's common stock.
(b)
During the nine months ended September 30, 2018, the Company granted stock options with a weighted average grant date fair value per share of $296.80, calculated using the Monte Carlo simulation model, which have vesting dates of March 31, 2022 and September 30, 2022.